Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Indivior PLC - Ordinary Shares (NQ:INDV)

30.49 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Indivior PLC - Ordinary Shares

< Previous 1 2 3 Next >
News headline image
Here's Why Indivior Stock Soared 15% Today ↗
This company is accelerating sales growth in its key prescription medication. 
Via The Motley Fool
News headline image
Earnings Scheduled For October 30, 2025 ↗
 
Via Benzinga
News headline image
INDIVIOR PLC (NASDAQ:INDV) Shows Top Technical and Setup Ratings for Potential Breakout ↗
INDIVIOR (INDV) shows strong technicals with a perfect 10 rating and a 9 setup score, signaling a potential breakout above $25.20 resistance. 
Via Chartmill
News headline image
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Indivior (INDV) Q2 EPS Jumps 104% ↗
Via The Motley Fool
News headline image
Roblox, Carvana, eBay, C.H. Robinson Worldwide, Huntington Ingalls Industries And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 31, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For April 24, 2025 ↗
 
Via Benzinga
News headline image
Indivior (INDV) Q1 2025 Earnings Call ↗
Via The Motley Fool
News headline image
A Look at Indivior's Upcoming Earnings Report ↗
 
Via Benzinga
News headline image
Indivior PLC: Is This Deeply Undervalued Stock A Hidden Gem? ↗
With a strong position in a niche yet vital therapeutic area, Indivior PLC benefits from durable brand equity, a specialized distribution network, and a long runway for product innovation. 
Via Talk Markets
Topics Stocks / Equities
News headline image
European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat ↗
Indivior's 2025 outlook missed estimates, citing Suboxone sales erosion. The company plans $100 million in cost cuts, with $50M reinvested in Sublocade. 
Via Benzinga
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
Earnings Scheduled For February 20, 2025 ↗
 
Via Benzinga
News headline image
Tesla, A. O. Smith And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
S&P Moves Lower; Domino's Pizza Posts Mixed Q3 Results ↗
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Surges 3%; Delta Air Lines Posts Downbeat Earnings ↗
 
Via Benzinga
News headline image
Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details ↗
Indivior cuts FY24 net revenue outlook due to competition and funding delays, causing a drop in share price. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Top 3 Health Care Stocks That May Explode This Month ↗
 
Via Benzinga
News headline image
Smith & Wesson Brands Reports Downbeat Results, Joins Planet Labs PBC, Broadcom And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
French Biotech Candidate For Cannabis Use Disorder Fails Phase 2B Clinical Trial, Indivior Will Not Exercise Option ↗
 
Via Benzinga
Topics Cannabis
News headline image
Health And Human Services Dept Orders OPVEE Nasal Spray For Emergency Fentanyl Overdose Response ↗
 
Via Benzinga
News headline image
Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder ↗
Addex Therapeutics stock surged after announcing clinical candidate selection with Indivior for substance use disorder treatment. Addex could receive up to $330 million plus royalties under the... 
Via Benzinga
News headline image
DexCom, Zynex, Olin And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
Pre-market stock movers are a hot topic on Thursday morning and we have all of the latest news traders need to know about them! 
Via InvestorPlace
News headline image
INDV Stock Earnings: Indivior Beats EPS, Beats Revenue for Q2 2024 ↗
INDV stock results show that Indivior beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Why Edwards Lifesciences Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.